Dr. Christina Sheil serves as Vice President of Pharmacovigilance at Arvinas. Dr. Sheil has over 17 years of Pharmacovigilance experience in both pharmaceutical and biotechnology settings. Dr. Sheil joins Arvinas after serving as the Head of Pharmacovigilance at Taiho Oncology, where she was responsible for leading the Pharmacovigilance Medical and Pharmacovigilance Operational teams. Dr. Sheil built a fully functioning Global Pharmacovigilance organization, upgrading the department from the regional model that was formerly in place. Prior to joining Taiho Oncology, Dr. Sheil was Executive Director and Head of Pharmacovigilance at Celldex Therapeutics, where she built the Pharmacovigilance function in a small biotech setting. Dr. Sheil also served as Global Head of Pharmacovigilance at Covance Inc., a large Contract Research Organization, as well as at Bracco Diagnostics, where she continued to build and improve department functioning globally for both organizations. She also has medical Pharmacovigilance experience serving as a Global Safety Officer early in her career at Sanofi, MedImmune, and Novartis, giving her both extensive pharmacovigilance medical and operational experience. Prior to joining the pharmaceutical industry, Dr. Sheil also worked at BioLife Plasma Services, where she was responsible for providing emergency medical oversight for patients, as well as completing all quality assurance deliverables for Good Clinical Practice (GCP), Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP) Compliance.
Dr. Sheil received her M.D. from Rutgers University and, after residency, practiced clinically for over 13 years in addition to subsequently owning her own private practice for six years.